Tower Research Capital LLC (Trc) Akebia Therapeutics, Inc. Transaction History

Tower Research Capital LLC (Trc)

$5.8 Billion
Q2 2024

A detailed history of Tower Research Capital LLC (Trc) transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 2,694 shares of AKBA stock, worth $3,583. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,694

Previous 34,647 92.22%

Holding current value

$3,583

Previous $63,000 96.83%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.86 - $1.63 $27,479 - $52,083	-31,953 Reduced 92.22%	2,694 $2,000
Q1 2024 May 15, 2024	BUY	$1.27 - $2.24 $41,837 - $73,792	32,943 Added 1933.27%	34,647 $63,000
Q4 2023 Feb 13, 2024	BUY	$0.8 - $1.28 $423 - $677	529 Added 45.02%	1,704 $2,000
Q3 2023 Nov 14, 2023	SELL	$0.87 - $1.84 $7,563 - $15,996	-8,694 Reduced 88.09%	1,175 $1,000
Q2 2023 Aug 14, 2023	SELL	$0.51 - $1.43 $6,643 - $18,628	-13,027 Reduced 56.9%	9,869 $9,000
Q1 2023 May 09, 2023	BUY	$0.56 - $1.15 $3,183 - $6,537	5,685 Added 33.03%	22,896 $13,000
Q4 2022 Feb 10, 2023	SELL	$0.25 - $0.58 $5,153 - $11,954	-20,612 Reduced 54.5%	17,211 $10,000
Q3 2022 Nov 10, 2022	SELL	$0.3 - $0.46 $483 - $740	-1,610 Reduced 4.08%	37,823 $12,000
Q2 2022 Aug 15, 2022	SELL	$0.32 - $0.67 $5,640 - $11,808	-17,625 Reduced 30.89%	39,433 $14,000
Q1 2022 May 12, 2022	SELL	$0.72 - $2.93 $14,921 - $60,721	-20,724 Reduced 26.64%	57,058 $41,000
Q4 2021 Feb 14, 2022	BUY	$2.26 - $3.34 $101,186 - $149,541	44,773 Added 135.64%	77,782 $176,000
Q3 2021 Nov 15, 2021	BUY	$2.35 - $3.88 $40,283 - $66,510	17,142 Added 108.04%	33,009 $95,000
Q2 2021 Aug 16, 2021	SELL	$2.83 - $4.2 $13,971 - $20,735	-4,937 Reduced 23.73%	15,867 $60,000
Q1 2021 May 17, 2021	BUY	$2.92 - $5.06 $20,402 - $35,354	6,987 Added 50.57%	20,804 $70,000
Q4 2020 Feb 16, 2021	SELL	$2.22 - $3.78 $342,996 - $584,021	-154,503 Reduced 91.79%	13,817 $38,000
Q3 2020 Nov 16, 2020	BUY	$2.39 - $13.08 $335,522 - $1.84 Million	140,386 Added 502.56%	168,320 $422,000
Q2 2020 Aug 13, 2020	BUY	$6.67 - $13.58 $185,652 - $377,985	27,834 Added 27834.0%	27,934 $379,000
Q1 2020 May 15, 2020	SELL	$4.1 - $10.24 $102 - $256	-25 Reduced 20.0%	100 $1,000
Q4 2019 Feb 07, 2020	SELL	$3.16 - $6.73 $24,148 - $51,430	-7,642 Reduced 98.39%	125 $1,000
Q3 2019 Nov 05, 2019	BUY	$3.55 - $5.4 $27,572 - $41,941	7,767 New	7,767 $30,000
Q2 2019 Aug 13, 2019	SELL	$4.1 - $8.05 $1,590 - $3,123	-388 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$5.41 - $8.73 $616 - $995	-114 Reduced 22.71%	388 $3,000
Q4 2018 Feb 14, 2019	BUY	$5.39 - $9.15 $2,705 - $4,593	502 New	502 $3,000
Q2 2018 Aug 15, 2018	SELL	$9.15 - $11.34 $26,718 - $33,112	-2,920 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$9.53 - $15.68 $16,620 - $27,345	1,744 Added 148.3%	2,920 $28,000
Q4 2017 Feb 09, 2018	SELL	$14.24 - $19.59 $4,243 - $5,837	-298 Reduced 20.22%	1,176 $17,000
Q3 2017 Nov 14, 2017	BUY	$13.06 - $19.67 $19,250 - $28,993	1,474	1,474 $29,000

Others Institutions Holding AKBA

# of Institutions

110

Shares Held

55.3M

Call Options Held

554K

Put Options Held

246K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $245M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account

Tower Research Capital LLC (Trc) Akebia Therapeutics, Inc. Transaction History